HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Buckley, C. Articles by Vincent, A. Search for Related Content PubMed PubMed Citation Articles by Buckley, C. Articles by Vincent, A.

Do titin and cytokine antibodies in MG patients predict thymoma or thymoma recurrence?

From the Neurosciences Group, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, UK.

Address correspondence and reprint requests to Professor Angela Vincent, Neurosciences Group, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, OX3 9DS, UK; e-mail: avincent{at}hammer.imm.ox.ac.uk

Background:— Patients with MG often have other autoantibodies in addition to those against the acetylcholine receptor (AChR). It has been suggested that antibodies to the muscle protein titin may be diagnostic of a thymoma, but they have also been found in patients with late-onset MG. Antibodies to certain cytokines have also been detected in patients with MG and thymoma, and it is not clear whether these antibodies could be more useful clinically. The authors measured antibodies against titin and the cytokines interferon (IFN) and interleukin 12 (IL12) in patients with MG and thymoma or thymoma recurrence, and in patients with MG but without thymoma presenting before (early-onset MG) or after (late-onset MG) 40 years of age.

Method:— Levels of titin, IFN, and IL12 antibodies were determined by radioimmunoassay in 191 patients with MG and 82 controls.

Results:— As previously reported, titin antibodies were uncommon in patients with early-onset MG. However, in patients with late-onset MG, titin antibodies had similar prevalence and levels to those in patients with MG and thymoma, although the antibodies were uncommon in patients between 40 and 60 years of age presenting without a tumor. By contrast, cytokine antibodies were more common in patients with thymoma than in patients without thymoma, and cytokine antibodies typically increased substantially if the thymoma recurred.

Conclusions:— Measurement of titin antibodies has limited use in predicting the presence of a tumor, unless the patient is less than 60 years of age, but measurement of IFN and IL12 antibodies may be helpful in identifying patients with a thymoma recurrence, particularly when mediastinal imaging is equivocal.

This article has been cited by other articles:

				A. Kontrogianni-Konstantopoulos, M. A. Ackermann, A. L. Bowman, S. V. Yap, and R. J. Bloch Muscle Giants: Molecular Scaffolds in Sarcomerogenesis Physiol Rev, October 1, 2009; 89(4): 1217 - 1267. [Abstract] [Full Text] [PDF]

				S. Suzuki, K. Utsugisawa, Y. Nagane, T. Satoh, Y. Terayama, N. Suzuki, and M. Kuwana Classification of Myasthenia Gravis Based on Autoantibody Status Arch Neurol, August 1, 2007; 64(8): 1121 - 1124. [Abstract] [Full Text] [PDF]

				Y Nemoto, S Kuwabara, S Misawa, N Kawaguchi, T Hattori, M Takamori, and A Vincent Patterns and severity of neuromuscular transmission failure in seronegative myasthenia gravis J. Neurol. Neurosurg. Psychiatry, May 1, 2005; 76(5): 714 - 718. [Abstract] [Full Text] [PDF]

				F. Romi, G. O. Skeie, N. E. Gilhus, and J. A. Aarli Striational Antibodies in Myasthenia Gravis: Reactivity and Possible Clinical Significance Arch Neurol, March 1, 2005; 62(3): 442 - 446. [Abstract] [Full Text] [PDF]

				H. Shiono, Y. L. Wong, I. Matthews, J.-L. Liu, W. Zhang, G. Sims, A. Meager, D. Beeson, A. Vincent, and N. Willcox Spontaneous production of anti-IFN-{alpha} and anti-IL-12 autoantibodies by thymoma cells from myasthenia gravis patients suggests autoimmunization in the tumor Int. Immunol., August 1, 2003; 15(8): 903 - 913. [Abstract] [Full Text] [PDF]

				R Voltz, W Albrich, R Hohlfeld, D Nagel, M Wick, T Kirchner, N Sommer, I Illa, H Kaminski, and F Schumm Anti-titin antibodies are not associated with a specific thymoma histology J. Neurol. Neurosurg. Psychiatry, February 1, 2003; 74(2): 282 - 282. [Full Text]

				A. Evoli, C. Minisci, C. Di Schino, F. Marsili, C. Punzi, A. P. Batocchi, P. A. Tonali, G. B. Doglietto, P. Granone, L. Trodella, et al. Thymoma in patients with MG: Characteristics and long-term outcome Neurology, December 24, 2002; 59(12): 1844 - 1850. [Abstract] [Full Text] [PDF]